Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Belimumab Treatment for IgG4-related Disease, a Prospective, Open-label Clinical Trial

NCT04660565 is registered in ClinicalTrials.gov with Peking Union Medical College Hospital as lead sponsor.

NCT NCT04660565
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04660565 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Belimumab Treatment for IgG4-related Disease, a Prospective, Open-label Clinical Trial
Lead sponsor
Peking Union Medical College Hospital
Phase
Phase 4
Overall status
Unknown status
Start date
January 31, 2021
Completion date
December 31, 2023
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

igg4-related disease